315 related articles for article (PubMed ID: 32056400)
21. Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study.
Okano T; Inui K; Tada M; Sugioka Y; Mamoto K; Wakitani S; Koike T; Nakamura H
Rheumatol Int; 2016 Mar; 36(3):349-57. PubMed ID: 26438386
[TBL] [Abstract][Full Text] [Related]
22. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
[TBL] [Abstract][Full Text] [Related]
23. Tocilizumab in the treatment of adult rheumatoid arthritis.
Sanmartí R; Ruiz-Esquide V; Bastida C; Soy D
Immunotherapy; 2018 Mar; 10(6):447-464. PubMed ID: 29495891
[TBL] [Abstract][Full Text] [Related]
24. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.
Daïen CI; Gailhac S; Audo R; Mura T; Hahne M; Combe B; Morel J
Rheumatology (Oxford); 2015 Apr; 54(4):601-8. PubMed ID: 25231180
[TBL] [Abstract][Full Text] [Related]
25. Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy.
Snir A; Kessel A; Haj T; Rosner I; Slobodin G; Toubi E
Clin Exp Rheumatol; 2011; 29(4):697-700. PubMed ID: 21813064
[TBL] [Abstract][Full Text] [Related]
26. Tocilizumab Increases Body Weight and Serum Adipokine Levels in Patients with Rheumatoid Arthritis Independently of Their Treatment Response: a Retrospective Cohort Study.
Choi IA; Sagawa A; Lee EY; Lee EB; Song YW
J Korean Med Sci; 2020 Jun; 35(22):e155. PubMed ID: 32508063
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study.
Tanaka E; Inoue E; Hoshi D; Shimizu Y; Kobayashi A; Sugimoto N; Shidara K; Sato E; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
Mod Rheumatol; 2015 Jul; 25(4):503-13. PubMed ID: 25547018
[TBL] [Abstract][Full Text] [Related]
28. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
Sagawa A
Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
[TBL] [Abstract][Full Text] [Related]
29. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522).
Karsdal MA; Schett G; Emery P; Harari O; Byrjalsen I; Kenwright A; Bay-Jensen AC; Platt A
Semin Arthritis Rheum; 2012 Oct; 42(2):131-9. PubMed ID: 22397953
[TBL] [Abstract][Full Text] [Related]
30. A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis.
Saito S; Suzuki K; Yoshimoto K; Kaneko Y; Matsumoto Y; Yamaoka K; Takeuchi T
Arthritis Res Ther; 2017 Oct; 19(1):231. PubMed ID: 29041951
[TBL] [Abstract][Full Text] [Related]
31. Prothrombotic biomarkers in patients with rheumatoid arthritis: the beneficial effect of IL-6 receptor blockade.
Gualtierotti R; Ingegnoli F; Griffini S; Grovetti E; Meroni PL; Cugno M
Clin Exp Rheumatol; 2016; 34(3):451-8. PubMed ID: 27086948
[TBL] [Abstract][Full Text] [Related]
32. The interleukin-20 receptor axis in early rheumatoid arthritis: novel links between disease-associated autoantibodies and radiographic progression.
Kragstrup TW; Greisen SR; Nielsen MA; Rhodes C; Stengaard-Pedersen K; Hetland ML; Hørslev-Petersen K; Junker P; Østergaard M; Hvid M; Vorup-Jensen T; Robinson WH; Sokolove J; Deleuran B
Arthritis Res Ther; 2016 Mar; 18():61. PubMed ID: 26968800
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-6 (IL-6) Receptor Antagonist Protects Against Rheumatoid Arthritis.
Li S; Wu Z; Li L; Liu X
Med Sci Monit; 2016 Jun; 22():2113-8. PubMed ID: 27322646
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-6 receptor blockade selectively reduces IL-21 production by CD4 T cells and IgG4 autoantibodies in rheumatoid arthritis.
Carbone G; Wilson A; Diehl SA; Bunn J; Cooper SM; Rincon M
Int J Biol Sci; 2013; 9(3):279-88. PubMed ID: 23493630
[TBL] [Abstract][Full Text] [Related]
35. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.
Maini RN; Taylor PC; Szechinski J; Pavelka K; Bröll J; Balint G; Emery P; Raemen F; Petersen J; Smolen J; Thomson D; Kishimoto T;
Arthritis Rheum; 2006 Sep; 54(9):2817-29. PubMed ID: 16947782
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis.
Thiolat A; Semerano L; Pers YM; Biton J; Lemeiter D; Portales P; Quentin J; Jorgensen C; Decker P; Boissier MC; Louis-Plence P; Bessis N
Arthritis Rheumatol; 2014 Feb; 66(2):273-83. PubMed ID: 24504799
[TBL] [Abstract][Full Text] [Related]
37. N-acetyl-l-cysteine controls osteoclastogenesis through regulating Th17 differentiation and RANKL production in rheumatoid arthritis.
Kim HR; Kim KW; Kim BM; Lee KA; Lee SH
Korean J Intern Med; 2019 Jan; 34(1):210-219. PubMed ID: 28286938
[TBL] [Abstract][Full Text] [Related]
38. Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial.
Edwards CJ; Östör AJK; Naisbett-Groet B; Kiely P
Rheumatology (Oxford); 2018 Jan; 57(1):84-91. PubMed ID: 29155973
[TBL] [Abstract][Full Text] [Related]
39. Pretreatment Prediction of Individual Rheumatoid Arthritis Patients' Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptor Biomarkers.
Uno K; Yoshizaki K; Iwahashi M; Yamana J; Yamana S; Tanigawa M; Yagi K
PLoS One; 2015; 10(7):e0132055. PubMed ID: 26176225
[TBL] [Abstract][Full Text] [Related]
40. Humanized antihuman IL-6 receptor antibody, tocilizumab.
Nishimoto N; Kishimoto T
Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]